Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of MK-7602 With and Without Pyronaridine in Healthy Participants
NCT07919028Phase 1Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2027
- Primary completion
- Apr 2027
01
Overview
Phase 1 trial of MK-7602 in malaria (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Curve From Time 0 to the Next Dosing Interval at 21 days, Maximum Plasma Concentration at 21 days and 2 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
MK-7602
03
Conditions
malaria
Beyond the preview
Go deeper on NCT07919028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07919028.